These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Addition and drug monitoring of mycophenolate mofetil for GVHD prophylaxis in unrelated bone marrow transplantation. Wada F; Kondo T; Yamamoto R; Yamagiwa T; Arai Y; Mizumoto C; Kanda J; Kitawaki T; Yamashita K; Takaori-Kondo A Bone Marrow Transplant; 2022 Jul; 57(7):1198-1200. PubMed ID: 35501566 [No Abstract] [Full Text] [Related]
43. Novel therapeutics for the treatment of graft-versus-host disease. Jacobsohn DA Expert Opin Investig Drugs; 2002 Sep; 11(9):1271-80. PubMed ID: 12225248 [TBL] [Abstract][Full Text] [Related]
44. Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease? Storb R; Antin JH; Cutler C Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S18-27. PubMed ID: 19857584 [TBL] [Abstract][Full Text] [Related]
45. Optimum use of tacrolimus in the prophylaxis of graft versus host disease. Uberti JP; Cronin S; Ratanatharathorn V BioDrugs; 1999 May; 11(5):343-58. PubMed ID: 18031144 [TBL] [Abstract][Full Text] [Related]
46. Tacrolimus: an alternative for graft-versus-host disease prevention. Lee TJ; Kennedy LA Ann Pharmacother; 2000 Mar; 34(3):377-81. PubMed ID: 10917386 [TBL] [Abstract][Full Text] [Related]
47. Tresperimus: a new agent for transplant tolerance induction. Simpson D Expert Opin Investig Drugs; 2001 Jul; 10(7):1381-6. PubMed ID: 11772258 [TBL] [Abstract][Full Text] [Related]
52. Is a little GVHD a good thing? Fry TJ Blood; 2009 Jun; 113(25):6274-5. PubMed ID: 19541836 [No Abstract] [Full Text] [Related]
53. Graft versus host disease: clinical evaluation, diagnosis and management. Espana EM; Shah S; Santhiago MR; Singh AD Graefes Arch Clin Exp Ophthalmol; 2013 May; 251(5):1257-66. PubMed ID: 23504086 [TBL] [Abstract][Full Text] [Related]
54. Novel pharmacotherapeutic approaches to prevention and treatment of GVHD. Jacobsohn DA; Vogelsang GB Drugs; 2002; 62(6):879-89. PubMed ID: 11929336 [TBL] [Abstract][Full Text] [Related]
55. Drug therapy for acute graft-versus-host disease prophylaxis. Simpson D J Hematother Stem Cell Res; 2000 Jun; 9(3):317-25. PubMed ID: 10894353 [TBL] [Abstract][Full Text] [Related]
56. New developments in the prophylaxis and treatment of graft versus host disease. Simpson D Expert Opin Pharmacother; 2001 Jul; 2(7):1109-17. PubMed ID: 11583062 [TBL] [Abstract][Full Text] [Related]
57. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation. Schwinghammer TL; Bloom EJ Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255 [TBL] [Abstract][Full Text] [Related]
58. Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants. Liesveld J; Duerst R; Rapoport A; Constine L; Abboud C; Packman C; Wedow L; Zwetsch L; McKenna B; Linder T; Silverman W; Swift S; Rowe J; DiPersio J Bone Marrow Transplant; 1999 Sep; 24(5):511-6. PubMed ID: 10482935 [TBL] [Abstract][Full Text] [Related]
59. [Immunosuppressive drugs in the prevention and treatment of GVHD after allogenic bone marrow transplantation]. Basić-Jukić N; Labar B Acta Med Croatica; 2003; 57(2):131-9. PubMed ID: 12879693 [TBL] [Abstract][Full Text] [Related]